Total Payments
$608,373
2024 Payments
$45,596
Companies
67
Transactions
1,255
Medicare Patients
5,479
Medicare Billing
$10.1M
Payment Breakdown by Category
Other$371,096 (61.0%)
Consulting$136,658 (22.5%)
Travel$48,403 (8.0%)
Food & Beverage$41,636 (6.8%)
Research$9,917 (1.6%)
Gifts$379.24 (0.1%)
Education$285.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $309,471 | 159 | 50.9% |
| Consulting Fee | $136,658 | 56 | 22.5% |
| Honoraria | $58,625 | 41 | 9.6% |
| Travel and Lodging | $48,403 | 115 | 8.0% |
| Food and Beverage | $41,636 | 850 | 6.8% |
| Unspecified | $9,917 | 24 | 1.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.5% |
| Gift | $379.24 | 1 | 0.1% |
| Education | $285.25 | 8 | 0.0% |
Payments by Type
General
$598,456
1,231 transactions
Research
$9,917
15 transactions
Ownership
$0
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $121,435 | 255 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $67,851 | 123 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $56,550 | 45 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $54,758 | 161 | $0 (2024) |
| UroGPO LLC | $37,339 | 49 | $0 (2020) |
| SN Holdings, LLC | $31,859 | 67 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $30,958 | 25 | $0 (2023) |
| Merck Sharp & Dohme LLC | $29,688 | 34 | $0 (2024) |
| PFIZER INC. | $26,807 | 67 | $0 (2024) |
| TOLMAR Pharmaceuticals, Inc. | $23,126 | 26 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,596 | 171 | Janssen Biotech, Inc. ($22,638) |
| 2023 | $56,443 | 161 | Janssen Biotech, Inc. ($13,080) |
| 2022 | $109,869 | 206 | Janssen Biotech, Inc. ($24,728) |
| 2021 | $80,762 | 121 | AstraZeneca Pharmaceuticals LP ($16,128) |
| 2020 | $79,757 | 67 | Bayer HealthCare Pharmaceuticals Inc. ($20,430) |
| 2019 | $100,107 | 183 | Janssen Biotech, Inc. ($34,816) |
| 2018 | $62,606 | 160 | Janssen Scientific Affairs, LLC ($24,018) |
| 2017 | $73,234 | 186 | Janssen Scientific Affairs, LLC ($23,882) |
All Payment Transactions
1,255 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: Oncology | ||||||
| 12/23/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $30.47 | General |
| Category: Oncology | ||||||
| 12/17/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: UROTHELIAL CANCER | ||||||
| 12/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 12/16/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $30.23 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $22.10 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Oncology | ||||||
| 11/26/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: UROTHELIAL CANCER | ||||||
| 11/19/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 11/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $116.71 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $164.57 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $98.67 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $26.90 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $31.59 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $126.54 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/04/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $21.99 | General |
| Category: HORMONE THERAPY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Travel and Lodging | In-kind items and services | $1,524.08 | General |
| Category: Diagnostic Imaging | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| APA-OUT-046_PHANTOM project Dr. Ben Lowentritt | Janssen Scientific Affairs, LLC | $5,500 | 3 |
| RETROSPECTIVE ANALYSIS OF THE IMPACT OF CORTICOSTEROID UTILIZATION ON CLINICAL AND ECONOMIC OUTCOMES IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER | Astellas Pharma Global Development | $2,662 | 9 |
| Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer An administrative claims analysis | Astellas Pharma Global Development | $1,755 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,423 | 2,046 | $4.1M | $2.1M |
| 2022 | 17 | 1,334 | 5,399 | $4.2M | $2.2M |
| 2021 | 18 | 1,383 | 1,885 | $5.9M | $3.1M |
| 2020 | 19 | 1,339 | 6,936 | $5.8M | $2.8M |
Total Patients
5,479
Total Services
16,266
Medicare Billing
$10.1M
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Office | 2023 | 22 | 48 | $3.7M | $2.0M | 53.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 323 | 418 | $111,188 | $27,196 | 24.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 86 | 241 | $40,006 | $12,763 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 112 | 129 | $38,829 | $12,662 | 32.6% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 13 | 69 | $29,325 | $9,302 | 31.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 25 | 60 | $22,200 | $6,848 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 42 | 42 | $17,556 | $5,606 | 31.9% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 42 | 42 | $24,150 | $4,484 | 18.6% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 52 | 88 | $11,088 | $3,557 | 32.1% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 20 | 59 | $9,617 | $3,083 | 32.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 276 | 362 | $7,329 | $3,013 | 41.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $8,800 | $2,701 | 30.7% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 31 | 38 | $16,530 | $2,272 | 13.7% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 16 | $5,680 | $1,820 | 32.1% |
| 99489 | Complex chronic care management services for two or more chronic conditions, each additional 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 15 | 23 | $4,324 | $1,384 | 32.0% |
| 76872 | Ultrasound scan of pelvic region through rectum | Facility | 2023 | 45 | 45 | $14,625 | $1,216 | 8.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 35 | $4,900 | $1,037 | 21.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 235 | 281 | $1,405 | $606.02 | 43.1% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 25 | 28 | $1,708 | $247.52 | 14.5% |
| Q2043 | Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | Office | 2022 | 24 | 50 | $3.8M | $2.1M | 55.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 329 | 432 | $114,912 | $28,418 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 116 | 143 | $43,043 | $14,573 | 33.9% |
| J9155 | Injection, degarelix, 1 mg | Office | 2022 | 12 | 3,680 | $29,440 | $11,780 | 40.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 28 | 62 | $22,940 | $7,601 | 33.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 41 | $17,138 | $5,965 | 34.8% |
About Dr. Benjamin Lowentritt, M.D
Dr. Benjamin Lowentritt, M.D is a Urology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578584959.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Lowentritt, M.D has received a total of $608,373 in payments from pharmaceutical and medical device companies, with $45,596 received in 2024. These payments were reported across 1,255 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($309,471).
As a Medicare-enrolled provider, Lowentritt has provided services to 5,479 Medicare beneficiaries, totaling 16,266 services with total Medicare billing of $10.1M. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Baltimore, MD
- Active Since 07/21/2006
- Last Updated 04/23/2014
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1578584959
Products in Payments
- ERLEADA (Drug) $82,265
- Erleada (Drug) $64,976
- PROVENGE (Drug) $55,846
- Nubeqa (Drug) $40,159
- LYNPARZA (Drug) $30,938
- Xofigo (Drug) $25,389
- XTANDI (Drug) $24,839
- ELIGARD (Drug) $23,097
- DARZALEX (Biological) $21,571
- KEYTRUDA (Biological) $21,466
- LUPRON DEPOT (Drug) $16,751
- Axumin (Drug) $15,985
- ORGOVYX (Drug) $10,739
- PYLARIFY (Drug) $10,473
- PLUVICTO (Drug) $10,197
- ENZALUTAMIDE (Drug) $7,454
- Xtandi (Drug) $6,436
- Rubraca (Drug) $4,700
- LYNPARZA (Biological) $3,921
- Biograph Horizon-3R (Device) $3,634
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Baltimore
Dr. George Mamo, M.d, M.D
Urology — Payments: $1.4M
Urology $1.4M
Brian Matlaga, M.d, M.D
Urology — Payments: $489,217
Urology $489,217
Ronald Tutrone, M.d, M.D
Urology — Payments: $148,343
Urology $148,343
Arthur Burnett, M.d, M.D
Urology — Payments: $135,418
Urology $135,418
Amin Herati, M.d, M.D
Urology — Payments: $131,870
Urology $131,870
Dr. Aaron Weinberg
Urology — Payments: $85,909
Urology $85,909